المؤلفون: Criss SD; Institute for Technology Assessment, Massachusetts General Hospital, Boston., Mooradian MJ; Massachusetts General Hospital Cancer Center, Boston.; Harvard Medical School, Boston, Massachusetts., Sheehan DF; Institute for Technology Assessment, Massachusetts General Hospital, Boston., Zubiri L; Massachusetts General Hospital Cancer Center, Boston.; Harvard Medical School, Boston, Massachusetts., Lumish MA; Massachusetts General Hospital Cancer Center, Boston., Gainor JF; Massachusetts General Hospital Cancer Center, Boston.; Harvard Medical School, Boston, Massachusetts., Reynolds KL; Massachusetts General Hospital Cancer Center, Boston.; Harvard Medical School, Boston, Massachusetts., Kong CY; Institute for Technology Assessment, Massachusetts General Hospital, Boston.; Harvard Medical School, Boston, Massachusetts.

المصدر: JAMA oncology [JAMA Oncol] 2019 Mar 01; Vol. 5 (3), pp. 358-365.

نوع المنشور: Comparative Study; Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Budgets* , Drug Costs*, Antibodies, Monoclonal/*administration & dosage , Antibodies, Monoclonal/*economics , Antineoplastic Agents, Immunological/*administration & dosage , Carcinoma, Non-Small-Cell Lung/*economics , Carcinoma, Non-Small-Cell Lung/*therapy , Chemoradiotherapy/*economics , Consolidation Chemotherapy/*economics , Lung Neoplasms/*economics , Lung Neoplasms/*therapy, Antibodies, Monoclonal/adverse effects ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/economics ; Carcinoma, Non-Small-Cell Lung/pathology ; Chemoradiotherapy/adverse effects ; Consolidation Chemotherapy/adverse effects ; Cost-Benefit Analysis ; Decision Support Techniques ; Disease Progression ; Drug Administration Schedule ; Humans ; Lung Neoplasms/pathology ; Markov Chains ; Models, Economic ; Neoplasm Staging ; Quality of Life ; Quality-Adjusted Life Years ; Time Factors ; Treatment Outcome ; United States

المؤلفون: Fan, Austin, Zhao, Beiqun, Vu, Peter, Abbadessa, Benjamin, Lopez, Nicole, Eisenstein, Samuel, Ramamoorthy, Sonia, Liu, Shanglei

المصدر: Journal of Clinical Medicine; Feb2024, Vol. 13 Issue 3, p781, 11p

مصطلحات موضوعية: RECTAL cancer, CONSOLIDATION chemotherapy, NEOADJUVANT chemotherapy, PATHOLOGIC complete response, INDUCTION chemotherapy, DATABASES, RECTAL surgery

مصطلحات جغرافية: UNITED States

المؤلفون: Rau RE; Division of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA., Dai Y; Department of Biostatistics, Colleges of Medicine, Public Health and Health Professions, University of Florida, Gainesville, Florida, USA., Devidas M; Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, Tennessee, USA., Rabin KR; Division of Pediatric Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA., Zweidler-McKay P; Immunogen, Inc., Waltham, Massachusetts, USA., Angiolillo A; Division of Pediatric Oncology, Children's National Medical Center, Washington, DC and the George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA., Schore RJ; Division of Pediatric Oncology, Children's National Medical Center, Washington, DC and the George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA., Burke MJ; Division of Pediatric Hematology-Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Salzer WL; U.S. Army Medical Research and Materiel Command, Fort Detrick, Frederick, Maryland, USA., Heerema NA; Department of Pathology, The Ohio State University Wexner School of Medicine, Columbus, Ohio, USA., Carroll AJ; Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA., Winick NJ; Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Hunger SP; Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Raetz EA; Department of Pediatrics, New York University Langone Medical Center, New York, New York, USA., Loh ML; Department of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California School of Medicine, San Francisco, California, USA., Wood BL; Department of Pathology and Laboratory Medicine, Children's Hospital of Los Angeles, University of Southern California, Los Angeles, California, USA., Borowitz MJ; Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

المصدر: Pediatric blood & cancer [Pediatr Blood Cancer] 2021 Apr; Vol. 68 (4), pp. e28929. Date of Electronic Publication: 2021 Feb 09.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: John Wiley Country of Publication: United States NLM ID: 101186624 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1545-5017 (Electronic) Linking ISSN: 15455009 NLM ISO Abbreviation: Pediatr Blood Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasm, Residual/*diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis, Child ; Child, Preschool ; Consolidation Chemotherapy ; Disease-Free Survival ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Infant ; Male ; Neoplasm, Residual/epidemiology ; Neoplasm, Residual/therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/epidemiology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Prognosis ; Risk Factors ; United States/epidemiology

المؤلفون: Stadtmauer EA; 1 University of Pennsylvania, Philadelphia, PA., Pasquini MC; 2 Medical College of Wisconsin, Milwaukee, WI., Blackwell B; 3 The Emmes Corporation, Rockville, MD., Hari P; 2 Medical College of Wisconsin, Milwaukee, WI., Bashey A; 4 BMT Group of Georgia, Atlanta, GA., Devine S; 5 The Ohio State University, Columbus, OH., Efebera Y; 5 The Ohio State University, Columbus, OH., Ganguly S; 6 University of Kansas Hospital, Kansas City, KS., Gasparetto C; 7 Duke University, Durham, NC., Geller N; 8 National Heart, Lung, and Blood Institute, Rockville, MD., Horowitz MM; 2 Medical College of Wisconsin, Milwaukee, WI., Koreth J; 9 Dana-Farber Cancer Institute, Boston, MA., Knust K; 3 The Emmes Corporation, Rockville, MD., Landau H; 10 Memorial Sloan Kettering Cancer Center, New York, NY., Brunstein C; 11 University of Minnesota, Minneapolis, MN., McCarthy P; 12 Roswell Park Cancer Institute, Buffalo, NY., Nelson C; 3 The Emmes Corporation, Rockville, MD., Qazilbash MH; 13 The University of Texas MD Anderson Cancer Center, Houston, TX., Shah N; 14 University of California, San Francisco, San Francisco, CA., Vesole DH; 15 Hackensack University, Hackensack, NJ., Vij R; 16 Washington University, St Louis, MO., Vogl DT; 1 University of Pennsylvania, Philadelphia, PA., Giralt S; 10 Memorial Sloan Kettering Cancer Center, New York, NY., Somlo G; 17 City of Hope, Los Angeles, CA., Krishnan A; 17 City of Hope, Los Angeles, CA.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2019 Mar 01; Vol. 37 (7), pp. 589-597. Date of Electronic Publication: 2019 Jan 17.

نوع المنشور: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*/adverse effects , Hematopoietic Stem Cell Transplantation*/mortality, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Bortezomib/*administration & dosage , Dexamethasone/*administration & dosage , Lenalidomide/*administration & dosage , Multiple Myeloma/*therapy, Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/adverse effects ; Consolidation Chemotherapy ; Dexamethasone/adverse effects ; Disease Progression ; Female ; Humans ; Lenalidomide/adverse effects ; Maintenance Chemotherapy ; Male ; Melphalan/administration & dosage ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Myeloablative Agonists/administration & dosage ; Progression-Free Survival ; Prospective Studies ; Remission Induction ; Reoperation ; Time Factors ; Transplantation, Autologous ; United States ; Young Adult

المؤلفون: Hakim H; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee.; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee., Dallas R; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee., Zhou Y; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee., Pei D; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee., Cheng C; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee., Flynn PM; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee.; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.; Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee., Pui CH; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Jeha S; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.

المصدر: Cancer [Cancer] 2016 Mar 01; Vol. 122 (5), pp. 798-805. Date of Electronic Publication: 2015 Dec 23.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Influenza, Human/*epidemiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/*epidemiology , Respiratory Syncytial Virus Infections/*epidemiology , Respiratory Tract Infections/*epidemiology, Acute Disease ; Adolescent ; Child ; Child, Preschool ; Cohort Studies ; Consolidation Chemotherapy/statistics & numerical data ; Female ; Hospitalization/statistics & numerical data ; Humans ; Incidence ; Induction Chemotherapy/statistics & numerical data ; Infant ; Male ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Retrospective Studies ; Risk Factors ; United States ; Young Adult

المؤلفون: Nagarajan A; Department of Hematology/Oncology, Cleveland Clinic, Weston, FL, 33331, USA. Electronic address: nagaraa@ccf.org.

المصدر: Surgical oncology [Surg Oncol] 2022 Aug; Vol. 43, pp. 101738. Date of Electronic Publication: 2022 Mar 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 9208188 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3320 (Electronic) Linking ISSN: 09607404 NLM ISO Abbreviation: Surg Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Neoadjuvant Therapy* , Rectal Neoplasms*/pathology, Chemoradiotherapy ; Fantasy ; Female ; Humans ; Male ; Neoplasm Staging ; Prospective Studies ; United States